The Latest in Lymphoma & Plasma Cell Disorders

German CLLM1 study: 4-year data raise concerns about lenalidomide maintenance

September 27, 2019

ICLL-07 trial: MRD-driven strategy yields prolonged survival

September 27, 2019

Daratumumab approved in combo with VTd for transplant-eligible multiple myeloma

September 26, 2019

Subcutaneous and IV daratumumab combos appear comparable in myeloma

September 26, 2019

Quadruplet prolongs progression-free survival in newly diagnosed myeloma

September 26, 2019

ASCT may cure follicular lymphoma for some rituximab-naive patients

September 24, 2019

Oral triplet shows promise for relapsed/refractory myeloma

September 22, 2019

CAR T-cell therapy found safe, effective for HIV-associated lymphoma

September 20, 2019

Combo could be new standard for transplant-eligible, newly diagnosed myeloma patients

September 20, 2019

Adding elotuzumab to lenalidomide/dexamethasone can prolong survival in relapsed/refractory myeloma

September 19, 2019

CT103A elicits responses after prior CAR T-cell relapse

September 19, 2019

Worse PFS when radiation is withheld in early-stage Hodgkin lymphoma

September 19, 2019

Staging PET/CT better defines extent of mantle cell lymphoma

September 19, 2019

Lymphoma & Plasma Cell Disorders

Melflufen-dexamethasone active in patients with relapsed/refractory myeloma and EMD

September 19, 2019

Could home care replace inpatient HSCT?

September 18, 2019